Skip to main content

Advertisement

SpringerLink
Log in

Subsequent entry biologics/biosimilars: a viewpoint from Canada

  • Review Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kanis JA, Reginster J-Y, Kaufman J-M et al (2012) A reappraisal of generic bisphonates in osteoporosis. Osteoporos Int 23:213–221

    Article  PubMed  CAS  Google Scholar 

  2. Colbert RA, Cronstein BN (2011) Biosimilars: the debate continues. Arthritis Rheum 63:2848–2850

    Article  PubMed  Google Scholar 

  3. Mullard A (2010) Hearing shines spotlight on biosimilar controversies. Nature Rev(Drug Discovery) 9:905–906

    Article  CAS  Google Scholar 

  4. Sekhon BS, Saluja V (2011) Biosimilars: an overview. Biosimilars 1:1–11

    Google Scholar 

  5. Kogan LA (2011) The US biologics price competition and Innovation Act of 2009 triggers public debate, regulatory/policy risks and international trade concerns. Global Trade Customs J 6:1–34

    Google Scholar 

  6. Joshi SR (2011) Biosimilar peptides: need for pharmacovigilance. J Assoc Physicians India 59 suppl:44–47

    PubMed  Google Scholar 

  7. Rudick RA, Simonian NA, Alam JA et al (1998) Incidence and significance of neutralizing antibodies to interferon-beta1a in multiple sclerosis. Neurology 50:1266–1272

    Article  PubMed  CAS  Google Scholar 

  8. Jelkmann W (2010) Biosimilar erythropoietins and other follow-on biologics: update on the European experience. Am J Haematol 85:771–780

    Article  Google Scholar 

  9. Gu N, Yi S, Kim T-E, Shin S-G, Jang I-J, Yu K-S (2011) Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence cross-over study in healthy Korean male volunteers. Clin Therapeutics 33:2029–2037

    Article  CAS  Google Scholar 

  10. http://www.biosimilars.ca/docs/BIOTECanada-SEB-GOWLINGS-082310.pdf

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. 562 Heritage Medical Centre, University of Alberta, Edmonton, AB, T6G2S2, Canada

    Anthony S. Russell

  2. 227-40 Finchgate Blvd, Brampton, ON, L6T3J1, Canada

    Vandana Ahluwalla

  3. University of Calgary, 3330 Hospital Dr. NW, Calgary, AB, Canada

    Cheryl Barnabe

  4. Vancouver Coastal Health Gordon and Leslie Diamond Centre, 2775 Laurel St. Suite 8205B, Vancouver, BC, V5Z1M9, Canada

    Shahin Jamal

  5. 112-725 Carmi Ave, Penticton, BC, V2A3G8, Canada

    Robert C. Offer

  6. Centre 103 Midtown Medical Centre, 39 23rd st. E, Saskatoon, SK, S7K0H6, Canada

    Wojciech P. Olszynski

  7. Division of Rheumatology, University of British Columbia, #802-1200 Burrard St., Vancouver, BC, V6Z2C7, Canada

    Kam Shojania

  8. University of Montreal, 1551 Ontario Est, Montreal, QC, H2L1S6, Canada

    Boulos Haraoui

Authors
  1. Anthony S. Russell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vandana Ahluwalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheryl Barnabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shahin Jamal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert C. Offer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wojciech P. Olszynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kam Shojania
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Boulos Haraoui
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony S. Russell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Russell, A.S., Ahluwalla, V., Barnabe, C. et al. Subsequent entry biologics/biosimilars: a viewpoint from Canada. Clin Rheumatol 31, 1289–1292 (2012). https://doi.org/10.1007/s10067-012-2066-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2066-5

Keywords

Search

Navigation